- £66.64m
- £35.36m
- £62.73m
- 71
- 78
- 14
- 55
REG - hVIVO PLC - £2m hMPV characterisation study contract
AnnouncementRCS - hVIVO PLC - Shionogi reports positive RSV trial results
AnnouncementREG - hVIVO PLC - RSV contract signed with Inhalon Biopharma
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementREG - hVIVO PLC - Acquisition: two Clinical Research Units from CRS
AnnouncementREG - hVIVO PLC - Trading update
AnnouncementREG - hVIVO PLC - LOI signed for Phase 3 Whooping Cough trial
AnnouncementREG - hVIVO PLC - £3.2m hLAB project
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementRCS - hVIVO PLC - hMPV challenge model update
AnnouncementRCS - hVIVO PLC - COVID-19 study published in Nature Communications
AnnouncementREG - hVIVO PLC - £11.5m RSV contract and notice of trading update
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementREG - hVIVO PLC - Holding(s) in Company
AnnouncementRCS - hVIVO PLC - Presentation at Jefferies London Healthcare Conf
AnnouncementREG - hVIVO PLC - Long Term Incentive Plan/ PDMR Notification
AnnouncementRCS - hVIVO PLC - Positive results from RSV human challenge trial
AnnouncementRCS - hVIVO PLC - Launch of full suite of hLAB standalone services
Announcement